Loading...

Grace Liang

TitleAssociate Physician
InstitutionUniversity of California San Diego
DepartmentNeurosciences
Address9500 Gilman Drive #0662
La Jolla CA 92093
vCardDownload vCard

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Thai-Cuarto D, O'Brien CF, Jimenez R, Liang G, Burke J. Cardiovascular Profile of Valbenazine: Analysis of Pooled Data from Three Randomized, Double-Blind, Placebo-Controlled Trials. Drug Saf. 2018 Apr; 41(4):429-440. PMID: 29218680.
      View in: PubMed
    2. Factor SA, Remington G, Comella CL, Correll CU, Burke J, Jimenez R, Liang G, O'Brien CF. The Effects of Valbenazine in Participants with Tardive Dyskinesia: Results of the 1-Year KINECT 3 Extension Study. J Clin Psychiatry. 2017 Nov/Dec; 78(9):1344-1350. PMID: 29141124.
      View in: PubMed
    3. Kane JM, Correll CU, Liang G, Burke J, O'Brien CF. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder. Psychopharmacol Bull. 2017 Aug 01; 47(3):69-76. PMID: 28839342.
      View in: PubMed
    4. Josiassen RC, Kane JM, Liang G, Burke J, O'Brien CF. Long-Term Safety and Tolerability of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia and a Diagnosis of Schizophrenia or Mood Disorder. Psychopharmacol Bull. 2017 Aug 01; 47(3):61-68. PMID: 28839341.
      View in: PubMed
    5. Correll CU, Josiassen RC, Liang G, Burke J, O'Brien CF. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Mood Disorder. Psychopharmacol Bull. 2017 Aug 01; 47(3):53-60. PMID: 28839340.
      View in: PubMed
    6. Chou KL, Elm JJ, Wielinski CL, Simon DK, Aminoff MJ, Christine CW, Liang G, Hauser RA, Sudarsky L, Umeh CC, Voss T, Juncos J, Fang JY, Boyd JT, Bodis-Wollner I, Mari Z, Morgan JC, Wills AM, Lee SL, Parashos SA. Factors associated with falling in early, treated Parkinson's disease: The NET-PD LS1 cohort. J Neurol Sci. 2017 Jun 15; 377:137-143. PMID: 28477684.
      View in: PubMed
    7. Hauser RA, Factor SA, Marder SR, Knesevich MA, Ramirez PM, Jimenez R, Burke J, Liang G, O'Brien CF. KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia. Am J Psychiatry. 2017 05 01; 174(5):476-484. PMID: 28320223.
      View in: PubMed
    8. Tetrud J, Nausieda P, Kreitzman D, Liang G, Nieves A, Duker AP, Hauser RA, Farbman ES, Ellenbogen A, Hsu A, Kell S, Khanna S, Rubens R, Gupta S. Conversion to carbidopa and levodopa extended-release (IPX066) followed by its extended use in patients previously taking controlled-release carbidopa-levodopa for advanced Parkinson's disease. J Neurol Sci. 2017 Feb 15; 373:116-123. PMID: 28131167.
      View in: PubMed
    9. Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial. JAMA. 2015 Feb 10; 313(6):584-93. PMID: 25668262; PMCID: PMC4349346.
    10. Stocchi F, Hsu A, Khanna S, Ellenbogen A, Mahler A, Liang G, Dillmann U, Rubens R, Kell S, Gupta S. Comparison of IPX066 with carbidopa-levodopa plus entacapone in advanced PD patients. Parkinsonism Relat Disord. 2014 Dec; 20(12):1335-40. PMID: 25306200.
      View in: PubMed
    11. Parashos SA, Luo S, Biglan KM, Bodis-Wollner I, He B, Liang G, Ross GW, Tilley BC, Shulman LM. Measuring disease progression in early Parkinson disease: the National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) experience. JAMA Neurol. 2014 Jun; 71(6):710-6. PMID: 24711047; PMCID: PMC4188544.
    12. Parashos SA, Swearingen CJ, Biglan KM, Bodis-Wollner I, Liang G, Ross GW, Tilley BC, Shulman LM. Determinants of the timing of symptomatic treatment in early Parkinson disease: The National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) Experience. Arch Neurol. 2009 Sep; 66(9):1099-104. PMID: 19597081; PMCID: PMC2839890.
    13. Kleiner-Fisman G, Liang G, Moberg PJ, Ruocco AC, Hurtig HI, Baltuch GH, Jaggi JL, Stern MB. Subthalamic nucleus deep brain stimulation for severe idiopathic dystonia: impact on severity, neuropsychological status, and quality of life. J Neurosurg. 2007 Jul; 107(1):29-36. PMID: 17639870.
      View in: PubMed
    14. Liang G, Chou KL, Baltuch GH, Jaggi JL, Loveland-Jones C, Leng L, Maccarone H, Hurtig HI, Colcher A, Stern MB, Kleiner-Fisman G, Simuni T, Siderowf AD. Long-term outcomes of bilateral subthalamic nucleus stimulation in patients with advanced Parkinson's disease. Stereotact Funct Neurosurg. 2006; 84(5-6):221-7. PMID: 17063043.
      View in: PubMed
    15. Siderowf A, Jaggi JL, Xie SX, Loveland-Jones C, Leng L, Hurtig H, Colcher A, Stern M, Chou KL, Liang G, Maccarone H, Simuni T, Baltuch G. Long-term effects of bilateral subthalamic nucleus stimulation on health-related quality of life in advanced Parkinson's disease. Mov Disord. 2006 Jun; 21(6):746-53. PMID: 16463342.
      View in: PubMed
    16. Liang G, de Miguel M, Gómez-Hernández JM, Glass JD, Scherer SS, Mintz M, Barrio LC, Fischbeck KH. Severe neuropathy with leaky connexin32 hemichannels. Ann Neurol. 2005 May; 57(5):749-54. PMID: 15852376.
      View in: PubMed
    17. Chou KL, Siderowf AD, Jaggi JL, Liang G, Baltuch GH. Unilateral battery depletion in Parkinson's disease patients treated with bilateral subthalamic nucleus deep brain stimulation may require urgent surgical replacement. Stereotact Funct Neurosurg. 2004; 82(4):153-5. PMID: 15475657.
      View in: PubMed
    Grace's Networks
    Concepts
    Derived automatically from this person's publications.
    _
    Co-Authors
    People in Profiles who have published with this person.
    _
    Related Authors
    People who share related concepts with this person.
    _